ClinicalTrials.Veeva

Menu

Procedural Advantages of a Novel Drug-Eluting Coronary Stent

U

University Hospital Heidelberg

Status

Completed

Conditions

Coronary Artery Disease

Treatments

Device: Synergy Stent
Device: Currently common drug-eluting stent (DES)

Study type

Interventional

Funder types

Other

Identifiers

NCT02881216
Synergy Stent

Details and patient eligibility

About

This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.

Enrollment

814 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • CAD for PCI, consecutive patients

Exclusion criteria

  • Age under 18
  • Bare Metal Stents or Scaffolds

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

814 participants in 2 patient groups

Common DES
Other group
Description:
Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
Treatment:
Device: Currently common drug-eluting stent (DES)
Synergy Stent
Other group
Description:
Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
Treatment:
Device: Synergy Stent

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems